<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248377</url>
  </required_header>
  <id_info>
    <org_study_id>Chula-ARC 002/10</org_study_id>
    <nct_id>NCT01248377</nct_id>
  </id_info>
  <brief_title>Skin Testing and ELISPOT Assay in Patients With a History of Non-Immediate Reactions to Cephalosporins</brief_title>
  <official_title>The Results of Skin Testing and The Detection of Cytokine Secretion From Drug Specific Peripheral Blood Mononuclear Cells Using ELISPOT Assay in the Diagnosis of Nonimmediate Reactions to Cephalosporins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the results of skin testing and ELISPOT assay in patients with a
      history of non-immediate reactions to cephalosporins
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a history of non-immediate reactions to cephalosporins will be tested by patch
      test and/or intradermal test. Peripheral blood mononuclear cells will be collected to
      analyzed cytokine secretions by ELISPOT assay
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The skin testing results of Cephalosporin skin test compared to ELISPOT assay</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The result of cross reactivity between Cephalosporins and other Betalactams determined by skin testing and ELISPOT assay</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>Cephalosporin Allergy</condition>
  <condition>Non-immediate Drug Reactions</condition>
  <arm_group>
    <arm_group_label>Cephalosporins allergic patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin tests and ELISPOT assay</intervention_name>
    <description>Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay</description>
    <arm_group_label>Cephalosporins allergic patients</arm_group_label>
    <other_name>Patch test</other_name>
    <other_name>Intradermal test</other_name>
    <other_name>ELISPOT</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PBMCs and serum will be collected for further analysis, if indicated
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with a history of non-immediate hypersensitivity reactions to cephalosporins
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a history of non-immediate hypersensitivity reactions to cephalosporins

          2. At least 18 years of age

        Exclusion Criteria:

          1. Suffering from severe systemic disease/ in bad health

          2. Being pregnant

          3. Patients with a history of immediate reactions to cephalosporin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jettanong Klaewsongkram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>October 9, 2011</last_update_submitted>
  <last_update_submitted_qc>October 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Jettanong Klaewsongkram</investigator_full_name>
    <investigator_title>Faculty of Medicine, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>Cephalosporins</keyword>
  <keyword>Drug hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

